Literature DB >> 32344007

In vitro and in vivo pharmacological characterization of the synthetic opioid MT-45.

S Bilel1, N J Azevedo2, R Arfè3, M Tirri1, A Gregori4, G Serpelloni5, F De-Giorgio6, P Frisoni1, M Neri1, G Calò2, M Marti7.   

Abstract

MT-45 is a synthetic opioid that was developed in the 1970s as an analgesic compound. However, in recent years MT-45 has been associated with multiple deaths in Europe and has been included in the class of novel psychoactive substances known as novel synthetic opioids (NSOs). Little is known about the pharmaco-toxicological effects of MT-45. Therefore, we used a dynamic mass redistribution (DMR) assay to investigate the pharmacodynamic profile of this NSO in vitro compared with morphine. We then used in vivo studies to investigate the effect of the acute systemic administration of MT-45 (0.01-15 mg/kg i.p.) on motor and sensorimotor (visual, acoustic and tactile) responses, mechanical and thermal analgesia, muscle strength and body temperature in CD-1 male mice. Higher doses of MT-45 (6-30 mg/kg i.p.) were used to investigate cardiorespiratory changes (heart rate, respiratory rate, SpO2 saturation and pulse distention). All effects of MT-45 were compared with those of morphine. In vitro DMR assay results demonstrated that at human recombinant opioid receptors MT-45 behaves as a potent selective mu agonist with a slightly higher efficacy than morphine. In vivo results showed that MT-45 progressively induces tail elevation at the lowest dose tested (0.01 mg/kg), increased mechanical and thermal antinociception (starting from 1 to 6 mg/kg), decreased visual sensorimotor responses (starting from 3 to 6 mg/kg) and reduced tactile responses, modulated motor performance and induced muscle rigidity at higher doses (15 mg/kg). In addition, at higher doses (15-30 mg/kg) MT-45 impaired the cardiorespiratory functions. All effects were prevented by the administration of the opioid receptor antagonist naloxone. These findings reveal the risks associated with the ingestion of opioids and the importance of studying these drugs and undertaking more clinical studies of the current molecules to better understand possible therapeutic interventions in the case of toxicity.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  DMR assay; MT-45; Morphine; Naloxone; Novel psychoactive substances; Synthetic opioids

Mesh:

Substances:

Year:  2020        PMID: 32344007     DOI: 10.1016/j.neuropharm.2020.108110

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports.

Authors:  Michal Ordak; Aleksandra Zmysłowska; Miłosz Bielski; Daniel Rybak; Maja Tomaszewska; Katarzyna Wyszomierska; Aleksandra Kmiec; Natalia Garlicka; Maria Zalewska; Michal Zalewski; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

2.  Comparison of N-methyl-2-pyrrolidone (NMP) and the "date rape" drug GHB: behavioral toxicology in the mouse model.

Authors:  Raffaella Arfè; Sabrine Bilel; Micaela Tirri; Paolo Frisoni; Giovanni Serpelloni; Margherita Neri; Federica Boccuto; Tatiana Bernardi; Federica Foti; Fabio De-Giorgio; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2021-04-21       Impact factor: 4.530

Review 3.  Epigenetic Studies for Evaluation of NPS Toxicity: Focus on Synthetic Cannabinoids and Cathinones.

Authors:  Leila Mazdai; Matteo Fabbri; Micaela Tirri; Giorgia Corli; Raffaella Arfè; Beatrice Marchetti; Sabrine Bilel; Eva Bergamin; Rosa Maria Gaudio; Michele Rubini; Fabio De-Giorgio; Matteo Marti
Journal:  Biomedicines       Date:  2022-06-13

Review 4.  An Update on the Implications of New Psychoactive Substances in Public Health.

Authors:  Ana Y Simão; Mónica Antunes; Emanuel Cabral; Patrik Oliveira; Luana M Rosendo; Ana Teresa Brinca; Estefânia Alves; Hernâni Marques; Tiago Rosado; Luís A Passarinha; Maristela Andraus; Mário Barroso; Eugenia Gallardo
Journal:  Int J Environ Res Public Health       Date:  2022-04-17       Impact factor: 4.614

Review 5.  Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications.

Authors:  Arianna Giorgetti; Jennifer P Pascali; Paolo Fais; Guido Pelletti; Andrea Gabbin; Giorgia Franchetti; Giovanni Cecchetto; Guido Viel
Journal:  Life (Basel)       Date:  2021-05-14

6.  Antinociceptive and Discriminative Stimulus Effects of Six Novel Psychoactive Opioid Substances in Male Rats.

Authors:  Ellen A Walker; Christina Chambers; Matthew G Korber; Srihari R Tella; Cassandra Prioleau; Li Fang
Journal:  J Pharmacol Exp Ther       Date:  2021-07-08       Impact factor: 4.402

7.  In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.

Authors:  Marthe M Vandeputte; Annelies Cannaert; Christophe P Stove
Journal:  Arch Toxicol       Date:  2020-07-31       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.